| Literature DB >> 23577266 |
Abstract
Frontal lobe syndromes, better termed as frontal network systems, are relatively unique in that they may manifest from almost any brain region, due to their widespread connectivity. The understandings of the manifold expressions seen clinically are helped by considering evolutionary origins, the contribution of the state-dependent ascending monoaminergic neurotransmitter systems, and cerebral connectivity. Hence, the so-called networktopathies may be a better term for the syndromes encountered clinically. An increasing array of metric tests are becoming available that complement that long standing history of qualitative bedside assessments pioneered by Alexander Luria, for example. An understanding of the vast panoply of frontal systems' syndromes has been pivotal in understanding and diagnosing the most common dementia syndrome under the age of 60, for example, frontotemporal lobe degeneration. New treatment options are also progressively becoming available, with recent evidence of dopaminergic augmentation, for example, being helpful in traumatic brain injury. The latter include not only psychopharmacological options but also device-based therapies including mirror visual feedback therapy.Entities:
Year: 2013 PMID: 23577266 PMCID: PMC3612492 DOI: 10.1155/2013/892459
Source DB: PubMed Journal: ISRN Neurol ISSN: 2090-5505
Figure 1Proposed core frontal systems.
Summary of cognitive psychological and neuroarcheological changes including brain size, reorganization, and NT changes.
| Frontal lobe size as expected within hominoid evolution | |
| Frontoparietal sensory motor integration including mirror neuron circuitry | |
| Lunate sulcus moves more posteriorly with reduction in primary visual cortex | |
| Petalias left occipital, right frontal (cerebral torque) | |
| Neuropil less dense | |
| BA 10 increased | |
| BA 13 decreased | |
| Temporal lobe increased in size | |
| Amygdala nucleus increased |
Figure 3Dopamine system.
Figure 4Serotonin system.
Figure 5The major fiber tracts of the brain, lateral and medial.
Figure 6Frontal subcortical circuits. Parallel circuits each with the same components. Exception; medial PFC via n. accumbens instead of caudate nucleus.
Figure 7Dorsolateral prefrontal executive frontal subcortical circuit.
Figure 8Basal ganglia anatomy.
Figure 2The 8 modulatory systems
Dementias have clinical pathological and molecular components.
| Domain | Pathology | Clinical | Subtypes |
|---|---|---|---|
| Linguistic | Tauopathies | Picks, SD, PPA. | 3 |
| Comportmental | Tauopathies | FTD behavioral | 1 |
| Amnestic | Amyloidopathies | AD | 4 |
| Movement dis. | Synucleinopathies | PD, DLB, PSP, CBD | 5 |
Core and extended emotional brain circuitry components.
| Core emotional brain | |
| OFC: orbitofrontal cortex | |
| VMPFC: ventromedial prefrontal cortex | |
| ACC: anterior cingulate cortex | |
| BF: basal forebrain | |
| NA: nucleus accumbens | |
| Extended emotional brain | |
| PAG: periaqueductal gray matter | |
| ATL: anterior temporal lobe | |
| AI: anterior insula | |
| PCC: posterior cingulate cortex | |
| VTA: ventral tegmental area |
Figure 9Frontal network syndromes may be caused by focal or diffuse processes with differing pathophysiologies.
Presentations of frontal network syndromes; clinical and radiological syndromes (Figure 10).
| (A) Lesion studies (multimodality MRI or CT imaging) | |
| (1) Symptom related: most conditions present with the triad of inattention, executive dysfunction, and dysmemory. A working memory disorder (worried well) as opposed to early Alzheimer's disease is also frequent. | |
| (2) Syndrome related: basic clinical (abulia, disinhibition, dysexecutive). | |
| (3) Syndrome pathophysiologically related. Examples include frontal stroke, herpes simplex encephalitis, leukoaraiosis, watershed infarction such as “Man-in-the-Barrel syndrome”, or tumor related such as the Foster Kennedy syndrome. | |
| (4) Anatomically lobar: motor, premotor prefrontal dorsolateral, prefrontal mediobasal, and prefrontal orbitofrontal. | |
| (5) Anatomically network: frontal subcortical circuits | |
| (6) Anatomically long range network: brainstem, cerebellar, occipital lesions associated with FNS | |
| (B) No radiological abnormality-neurotransmitter syndromes | |
| Serotonin syndrome | |
| Neuroleptic malignant syndrome | |
| Malignant hyperpyrexia | |
| Cholinergic and anticholinergic toxidromes | |
| Paroxysmal autonomic instability and dystonia syndrome (PAIDS) | |
| (C) Synaptopathies (for example Limbic encephalitis) | |
| Disorders with antibodies against synaptic proteins such as NMDA, AMPA, and GABA-B receptors. Present with seizures and encephalopathies and yet are treatable [ | |
| (D) Networktopathies and participatory networks (f-MRI) | |
| The default mode network, salience network, and attentional network may be evaluated by f-MRI (e.g., abnormal in AD, FTD, TBI, MS, depression, e.g.,) [ | |
| Functional MRI-task-related activity seen, for example, with the Stroop, Word List Generation tests, and Wisconsin Card Sorting Test activating particular networks [ |
Additional neuropathological states and conditions in which FNS is invariably part of the neurological syndrome [22–24].
| Subcortical gray matter | |
| HIV dementia | |
| Wilson's disease | |
| Huntington's | |
| Neuroacanthocytosis syndrome | |
| Prionopathies (Creutzfeldt-Jakob, GSS FFI, and BSE) | |
| Fahr's syndrome—calcification of the BG | |
| Pantothenate kinase 2 associated neurodegeneration (PANK2) | |
| Adult neuronal ceroid lipofuscinosis | |
| Subcortical white matter | |
| Leukodystrophy disorders (metachromatic, Krabbe's, adrenal, orthochromatic) | |
| Fabry's disease | |
| Vanishing white matter disease | |
| Mixed cortical and subcortical pathology | |
| Vasculitides | |
| Meningitis/encephalitis | |
| CADASIL | |
| Alexander's disease | |
| Canavan disease | |
| Cerebrotendinous xanthomatosis | |
| Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) or Nasu-Hakola disease | |
| Mitochondrial diseases (MELAS, MERFF, and Kearns Sayre) |
Figure 10FTD phenotypes. New International criteria for diagnosis of FTD.
Figure 11Leukoaraiosis: A common causes of frontal network syndromes.
Neuropathologic subtypes.
| Histopathology | Subtypes | Clinical | Chromosome |
|---|---|---|---|
| Tauoapthy | PiD | bvFTD, PNFA | 17 (MAPT) |
| PSP | PSP | ||
| CBD | CBD, PNFA | ||
| AGD | bvFTD, MND | ||
| MST | |||
|
| |||
| TDP-43 | Type 1 | bvFTD | |
| Type 2 | SD, MND | 9 (IFT74) | |
| Type 3 | bvFTD, SD, PNFA | 17 (PGRN) | |
| Type 4 | bvFTD, myopathy, Paget's | 9 (VCP) | |
|
| |||
| FTLD-UPS | FTD 3 | bvFTD | 3 (CHMP2B) |
|
| |||
| BIBD | — | FTD-MND | |
|
| |||
| FTLD-IF | — | — | — |
|
| |||
| FTLD-ni | — | — | — |
PiD: Pick's disease, PSP: progressive supranuclear palsy, CBD: cortico-basal-ganglionic degeneration, AGD: argyrophilic grain disease, MND: motor neuron disease, PNFA: progressive nonfluent aphasia, SD: semantic disease/variant, MST: sporadic multisystem tauopathy, BIBD: basophilic inclusion body disease, FTLD IF: FTLD with intermediate filament inclusions, FTLD ni: FTLD with no inclusions, FUS: fused in sarcoma, NIF: neuronal intermediate filaments, VCP: valosin containing protein, CMBP 2B: charged multivesicular body protein 2B, MAPT: microtubule associated protein tau, TDP-43: TAR DNA binding protein 43, IFT74: intraflagellar transport protein 74.
Modified from Josephs [25].
Figure 12Watershed infarction (arrows).
Figure 13Tegmentothalamic infarction due to deep venous system thrombosis postpartum.
Figure 14Discreet hemorrhage in left angular gyrus region presenting with Gerstmann's syndrome.
Conditions that can present with white matter hypertensities on MRI brain scan.
| (i) Cerebrovascular (HTN, Atrial fibrillation, DM, Homocysteine) | |
| (ii) Alzheimer's | |
| (iii) APOE 4 status | |
| (iv) Trauma | |
| (v) Migraine | |
| (vi) AIDS dementia | |
| (vii) Psychiatric (bipolar, schizophrenia) | |
| (viii) Autism | |
| (ix) CADASIL | |
| (x) Wilson's, Hallervorden Spatz | |
| (xi) Dystonia | |
| (xii) Neuroacanthocytosis | |
| (xiii) Fragile X associated tremor and ataxia | |
| (xiv) Susac's syndrome | |
| (xv) Myotonic dystrophy type 1 and 2 | |
| (xvi) Hypoglycemic encephalopathy | |
| (xvii) Leukodystrophies (Metachromatic, Krabbe) | |
| (xviii) Multiple sclerosis | |
| (xix) Autoimmune vasculitis (SLE, Sjogren's) |
Junque Leukoaraiosis grading [26].
| Evaluate 5 areas in each hemisphere | |
| (i) Centrum semiovale in frontal region | |
| (ii) Centrum semiovale parietal region | |
| (iii) White matter surrounding frontal horn | |
| (iv) White matter surrounding corpus of the lateral ventricle | |
| (v) White matter surrounding the atrium and occipital horn of lateral ventricle | |
|
| |
| Numerical scores 1–4 of T2 hyperintensity | |
| (i) No changes | 0 |
| (ii) <25% | 1 |
| (iii) 25%–50% | 2 |
| (iv) 50%–75% | 3 |
| (v) >75% | 4 |
|
| |
| Total score | 0–40 |
Pathophysiology of concussion and traumatic brain injury [27, 28].
| (1) Excessive or indiscriminate release of excitatory neurotransmitters | |
| Increased glutamate binding to NMDA receptors causes efflux of potassium out of the cell, influx of calcium, and alteration of the neuronal membrane potential: Na-K pump is upregulated and consequently requires more ATP. | |
| (2) An uncoupling of glucose metabolism and cerebral blood flow occurs | |
| A glucose hypermetabolism ensues and there is a simultaneous diminished cerebral blood flow, which may be reduced as much as 50% of normal | |
| Even more important from a clinical point of view, the cerebral glucose may be reduced for up to 4 weeks | |
| (3) Calcium accumulation occurs | |
| Intracellular Ca++ accumulation causes mitochondrial impairment, cell death by phosphokinases, protein kinases, NO synthase, endonucleases, and calpains and plasmalogenase culminating in free radical accumulation and apoptosis. | |
| (4) Chronic alterations in neurotransmission | |
| Glutaminergic, cholinergic, and adrenergic alterations account for the memory and cognitive deficits seen after concussion and TBI. The neurochemical findings include LTP may be persistently impaired after TBI, loss of cholinergic input from the basal forebrain, and impaired GABA inhibitory function of the hippocampal dentate granule cells occurs which predisposes the injured brain to seizures. | |
| (5) Axonal disconnection occurs | |
| Diffuse axonal injury may occur due to mechanical stretching or calcium influx with subsequent microtubule breakdown. Axonal bulbs may result due to intra-axonal cytoskeletal injury, accumulation of organelles at the site of damage axonal damage with localized axonal swellings appearing (axonal bulbs). Secondary axonotomy (constrictions) with axonal disconnection may occur many weeks after TBI. |
Different classification systems and current status of antibodies implicated: autoimmune dementia may be idiopathic or secondary to cancer (paraneoplastic) [29].
| Eponymous | |
| Morvan syndrome | |
| Syndromic | |
| Progressive encephalomyelopathy with rigidity and myoclonus | |
| Serologically | |
| VGKC antibody associated encephalopathy | |
| Pathologically | |
| Nonvasculitic autoimmune meningoencephalitis | |
| Antibodies | |
| VGKC | |
| NMDA receptor antibody | |
| AMPA receptor | |
| GABAB receptor | |
| GAD 65 | |
| ANNA-1 (anti-Hu) | |
| ANNA-2 (anti-Ri) | |
| ANNA-3 | |
| AGNA (SOX-1) | |
| PCA-2 | |
| CRMP-5 (anti-CV2) | |
| Amphiphysin | |
| Ma/Ta proteins | |
| NMO-IgG |
VGKC: voltage gated potassium channel, NMDA: N-methyl D-aspartate, AMPA: alpha-amino-3-hydroxy-5-methyl-isoxazolepropionic acid, GABA: gamma-aminobutyric acid, GAD: glutamic acid decarboxylase 65, ANNA, antineuronal nuclear antibody, AGNA: antiglial nuclear antibody, PCA: Purkinje cell cytoplasmic antibody, CRMP 5: collapsing response mediator protein 5, NMO: neuromyelitis optica IgG antibodies (modified from Mckeon et al.) [30].
Viral, bacterial, fungal, and parasitic brain infections with frontal subcortical circuit involvement.
| Viral | |
| HIV encephalopathy | |
| JC virus—progressive multifocal leukoencephalopathy (PML) | |
| Herpes simplex encephalitis | |
| West Nile virus | |
| Tegmentothalamic syndrome (various) | |
| Bacterial | |
| Tuberculous meningitis | |
| Neisseria meningitides | |
| Hemophilus influenza | |
| Listeria monocytogenes | |
| Whipple's disease | |
| Spirochetal | |
| Borreliosis (Lyme disease) | |
| Neurolues | |
| Fungal | |
| Cryptococcal meningitis | |
| Histoplasmosis | |
|
| |
|
| |
| Candida species | |
| Prionopathies | |
| Creutzfeldt Jakob disease (CJD) | |
| Variant Creutzfeldt-Jakob disease (V-CJD) | |
| Kuru | |
| Fatal familial insomnia (FFI) | |
| Gerstmann-Straeussler-Scheinker syndrome (GSS) | |
| Parasitic | |
| Malaria | |
| Bilharziasis | |
| Cysticercosis | |
| Toxoplasmosis | |
| Amoebic meningitis ( |
Cerebral vasculitides and autoimmune disorders classification.
| Primary | |
| Polyarteritis nodosa | |
| Cogan's syndrome | |
| Churg-Strauss syndrome | |
| Temporal | |
| Takayasu's Disease | |
| Granulomatous | |
| Lymphomatoid | |
| Wegener's | |
| Kawasaki | |
| Susac's | |
| Hypersensitivity | |
| Buergers | |
| Acute posterior multifocal placoid pigment epitheliopathy | |
| Kohlmeier Degos | |
| Isolated angiitis of the CNS | |
| Secondary to autoimmune and systemic diseases | |
| Sarcoidosis | |
| Rheumatoid arthritis | |
| Systemic lupus erythematosus | |
| Sjogrens | |
| Behcet's | |
| Scleroderma | |
| Mixed connective tissue disease | |
| Dermatomyositis | |
| Ulcerative colitis | |
| Coeliac disease | |
| Secondary—infectious related | |
| Human immunodeficiency virus | |
| Varicella zoster | |
| Herpes zoster | |
| Cytomegalovirus | |
| Mycotic | |
| Lues disease | |
|
| |
| Tuberculosis | |
| Cysticercosis | |
| Bacterial meningitis | |
| Secondary to neoplasia | |
| Hodgkins and non-Hodgkins | |
| Malignant histiocytosis | |
| Hairy cell leukemia | |
| Secondary to illicit drugs | |
| Cocaine | |
| Sympathomimetic agents | |
| Amphetamine |
Anatomical and functional imaging categories and examples of major disease entities associated with frontal network syndromes [31–34].
| (A) MRI multimodality | |
| MRI (routine series) | |
| T1/T2, FLAIR, GRE, and MRA to detect degree of concomitant vascular disease, atrophy pattern, and other secondary pathologies | |
| MRI—DTI | |
| Fiber tract pathology especially in traumatic brain injury, multiple sclerosis | |
| MRI quantitative atrophy estimation | |
| Different patterns of the major dementia syndromes (Seeley et al. [ | |
| MRI—perfusion | |
| Perfusion as a reflection of hypometabolism, similar to SPECT (perfusion) and PET (metabolism) patterns of abnormality | |
| MR spectroscopy | |
| Biochemical analysis of NAA, choline, lactate particularly useful in brain tumor diagnosis | |
| (B) SPECT | |
| Hypoperfusion (in vascular or hypometabolism) | |
| Hyperperfusion for example with ictal foci. | |
| (C) PET brain | |
| Hypometabolic patterns in different dementias | |
| (D) Intrinsic state connectivity maps | |
| Default mode | |
| Salience network | |
| Attentional network | |
| Visual network | |
| Auditory network | |
| (E) Quantitative EEG and MEG | |
| AD reduced connectivity of alpha and beta in frontoparietal and frontotemporal regions | |
| Parkinson's increased connectivity of alpha and beta locally and globally | |
| DLBD reduced connectivity alpha range locally and globally. |
Adapted and modified from [31, 32].
PET brain patterns in dementias.
| Dementia subtype | 18 FFDG PET hypometabolism pattern |
|---|---|
| Alzheimer | Relatively symmetric parietotemporal, medial temporal, posterior cingulate, and frontal association cortex to lesser degree |
| AD variant (PCAS) | Occipital hypometabolism predominates |
| FTD behavioral variant | Frontal and anterior temporal hypometabolism |
| PDD | Temporoparietal, may be similar to AD |
| DLBD | Occipital and temporal hypometabolism |
| CVD | Cortical and subcortical, singular or multifocal, correlating with structural imaging abnormality |
| CBD | Global reduction in metabolism as well as asymmetric prefrontal, premotor, sensorimotor superior temporal, parietal hypometabolism with thalamic hypometabolism contralateral to limb apraxia |
| Huntington's | Caudate nucleus hypometabolism and frontal association cortex to a lesser degree |
| PSP | Caudate nucleus, putamen, thalamus, pons, and superior and anterior frontal cortex |
PCAS: posterior cortical atrophy syndrome.
PSP: progressive supranuclear palsy.
FDG PET increases diagnostic accuracy beyond that derived from clinical evaluation. Adapted and modified from [35].
Intrinsic connectivity network patterns in dementias.
| Dementia subtype | Intrinsic connectivity pattern |
|---|---|
| Alzheimer | Default mode network shows reduced connectivity |
| FTD behavioral variant | Salience network shows reduced connectivity |
| Parkinson's | BN-thalamocortical loops show |
| DLBD | Uncertain at present but may show ascending brainstem projection system |
| CBG | Uncertain |
FTD: frontotemporal lobe disorder, DLDB: diffuse lewy body disease, BN: basal nuclei (basal ganglia), CBG: corticobasal-ganglionic disorder.
Adapted and modified from [35].
Future treatment strategies proposed for the stroke model.
| (1) Small molecules (monoaminergic systems, antibodies against axonal growth inhibitor Nogo-A) | |
| (2) Growth factors (fibroblast growth factor, brain derived neurotrophic factor, hematopoietic growth factor, granulocyte colony stimulating factor) | |
| (3) Cell-based therapies (endothelial progenitor cells, intracerebral transplantation of cultured neuronal cells, intravenous mesenchymal stromal cells) | |
| (4) Electromagnetic stimulation | |
| (5) Device-based therapies | |
| (6) Task orientated and repetitive training-based interventions |
Modified from [36].
Proposed approach of neurological/neuropsychiatric disorders.
| (1) Use the list of symptoms and signs to form an overall generic categorical diagnostic syndromes such as abulic/apathetic, disinhibited/dysexecutive, depression, and obsessive compulsive disorders. This is a clinical assessment that may be aided by inventories, scales, or diagnostic manuals such as DSM IV | |
| (2) Component analysis in terms of the core frontal functions embedded in the 5 currently appreciated frontal subcortical behavioral circuits | |
| (3) Establish the cerebrovascular component and its specific treatment | |
| (4) Establish whether medical conditions (hypothyroidism, low B12, Vit D, folate) are contributing to the cognitive impairment | |
| (5) Establish contribution of impaired sleep (sleep apnea, dyssomnia) | |
| (6) Establish contribution of centrally acting drugs and discontinue, reduce dosage or change to another less conflicting drug if possible. | |
| (7) Use known information about neurotransmitter deficiencies in these syndromes and/or FSC's and target with specific pharmacological and behavioral treatment approaches. | |
| (8) Counsel with respect to the 5 principal components of brain health |
The more common clinical disorders presenting with neurological and/or psychiatric FNS.
| (I) Neurological | |
|---|---|
| (a) Neurodegenerative | |
| Frontotemporal disorders (FTLD) | |
| Alzheimer's disease (AD) | |
| Cognitive vascular disorders (CVD) | |
| Frontal variant of AD | |
| Corticobasal-ganglionic disorders (CBD) | |
| (b) Cerebrovascular and cognitive vascular disorders | |
| Bland infarcts | |
| Strategic infarct | |
| Subcortical infarct | |
| Watershed infarct | |
| Frontal, sometimes bilateral as with common origin of both anterior cerebral arteries off the anterior communicating artery | |
| Leukoaraiosis | |
| Brainstem infarct | |
| Cerebellar infarct | |
| Strategic infarct such as caudate nucleus, basal ganglia, and thalamus | |
| Frontal lobe amyloid angiopathy | |
| Hemorrhage | |
| Amyloid angiopathy | |
| Microhemorrhage | |
| Subcortical hypertensive related | |
| (c) Tumors | |
| Frontal lobe meningioma (Foster Kennedy syndrome) | |
| (d) Traumatic brain injury | |
| Diffuse axonal injury | |
| Chronic subacute encephalopathy | |
| (e) Multiple sclerosis | |
| (f) Parkinson's, Huntington's | |
| (g) Frontal lobe epilepsies | |
| (h) Normal pressure hydrocephalus | |
| (i) Neurotoxicology—alcohol | |
|
| |
| (II) Psychiatric | |
|
| |
| Schizophrenia | |
| Mania and hypomania | |
| Depression | |
| Anxiety | |
| Obsessive compulsive | |
| Tourette's | |
| Attention deficit hyperactivity disorder (ADHD) | |
| Autism | |
| William's syndrome | |
| Pervasive developmental disorders | |